The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Market Size Of The Antiobesity Market In 2026 And What Value Is Projected For 2030?
The antiobesity market has shown significant expansion in recent years. Its valuation is anticipated to climb from $4.1 billion in 2025 to $4.47 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.0%. This past growth can be ascribed to escalating global obesity rates, the limited efficacy of interventions solely based on lifestyle changes, the accessibility of appetite suppressants, an increasing prevalence of metabolic disorders, and physician-guided weight management strategies.
The antiobesity market is projected to experience swift expansion in the upcoming years. It is forecast to reach $6.56 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.0%. This growth during the forecast period stems from factors such as the increasing incidence of diabetes and obesity, advancements in hormone-based medications, broadened reimbursement coverage, enhanced awareness regarding obesity, and the demand for long-term weight management solutions. Key trends anticipated in this period encompass the quick uptake of glp-1 based treatments, a rising inclination towards prescription weight loss medications, the increased application of combination antiobesity therapies, an elevated emphasis on sustained weight management, and expanded access to obesity treatment options.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3403&type=smp
What Major Drivers Are Influencing Demand In The Antiobesity Market?
The increasing incidence of obesity is expected to stimulate the expansion of the anti-obesity drugs market moving forward. Obesity is a persistent metabolic condition defined by an excessive accumulation of body fat, which heightens the risk of significant health complications, including diabetes, cardiovascular diseases, osteoarthritis, and certain cancers. This growing prevalence of obesity is attributed to a greater intake of ultra-processed foods, which are high in sugars, unhealthy fats, and refined carbohydrates, combined with inactive lifestyles that reduce physical movement. This rise in obesity’s commonness is fueling the demand for effective medical interventions against obesity, supportive weight management therapies, and long-term treatment options to alleviate associated health risks and enhance patient outcomes. For instance, in March 2024, the World Obesity Federation, a UK-based organization focused on obesity research and advocacy, projected that 79% of adults with overweight and obesity and 88% of children with overweight and obesity will be living in low and middle income countries by 2035. As a result, the escalating rate of obesity prevalence is a key driver for the growth of the anti-obesity drugs market.
What Are The Key Segments Of The Antiobesity Market?
The antiobesity market covered in this report is segmented –
1) By Drug Class: Peripherally Acting Anti-Obesity Drugs, Centrally Acting Anti-Obesity Drugs
2) By Type: Prescription Drugs (Rx), OTC Drugs
3) By Medication: Monotherapies, Polytherapies
Subsegments:
1) By Peripherally Acting Anti-Obesity Drugs: Orlistat, Lorcaserin
2) By Centrally Acting Anti-Obesity Drugs: Phentermine, Topiramate, Naltrexone-Bupropion Combination, Liraglutide
What Key Trends Are Influencing The Development Of The Antiobesity Market?
Leading companies in the antiobesity market are concentrating on product innovation and new formulations, such as dual glucose-dependent insulinotropic peptide receptor agonists. This focus aims to achieve more effective weight loss, better metabolic outcomes, and improved patient tolerability. These advanced therapies harness synergistic actions on appetite suppression, insulin sensitivity, and energy expenditure, delivering superior efficacy compared to older generation GLP-1-only treatments. For instance, in December 2024, Eli Lilly, a US-based pharmaceutical company, obtained FDA approval for Zepbound (tirzepatide). This made it the first and only prescription dual GIP/GLP-1 agonist to be approved for chronic weight management. Tirzepatide has demonstrated strong weight-loss efficacy, with phase 3 trial participants achieving significant reductions in body weight. With its new indication, Zepbound is expected to solidify Lilly’s leadership in the precision obesity therapy space, meeting the rising demand for long-acting, high-efficacy treatments.
Who Are The Leading Companies Operating In The Antiobesity Market?
Major companies operating in the antiobesity market are Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd.
Read the full antiobesity market report here:
https://www.thebusinessresearchcompany.com/report/antiobesity-global-market-report
Which Region Shows The Strongest Potential For Future Growth In The Antiobesity Market?
North America was the largest region in the anti-obesity market in 2025. Middle East is expected to be the fastest-growing region in the antiobesity market. The regions covered in the antiobesity market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Antiobesity Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3403&type=smp
Browse Through More Reports Similar to the Global Antiobesity Market 2026, By The Business Research Company
Antiobesity Market Report 2026
https://www.thebusinessresearchcompany.com/report/antiobesity-global-market-report
Antimony Market Report 2026
https://www.thebusinessresearchcompany.com/report/antimony-global-market-report
Antivenom Market Report 2026
https://www.thebusinessresearchcompany.com/report/antivenom-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model